BMS bets on Janux’s novel solid tumour therapy through $850m deal
Bristol Myers Squibb (BMS) has added to its oncology pipeline through an exclusive global licensing agreement with Janux Therapeutics. This deal …
Post
-
-
US set to officially exit WHO in culmination of Trump’s domestic push
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to …
-
The new safety mandate driving AI-ready pharmacovigilance
Regulatory expectations in the drug safety industry have evolved faster in the past five years than in the previous two …
-
Heart disease and stroke deaths take a downturn, AHA report reveals
A new report from the American Heart Association (AHA) has found that US cardiovascular disease (CVD)-related deaths declined between 2022 …
-
Johnson & Johnson reports 9.1% increase in sales for Q4 2025
Johnson & Johnson (J&J) has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising …
-
Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis
Opna Bio has received the US Food and Drug Administration’s (FDA) orphan drug designation for OPN-2853 (zavabresib), a bromodomain and …
-
Davos26: Trump says tariff threats helped fix US drug pricing ‘unfairness’
The threat of tariffs was necessary to get major drugmakers and foreign leaders on board with drug pricing reforms in …
-
Walking the pharma supply chain tightrope requires more than precision
Between 2023 and 2025, hundreds of thousands of Type 2 diabetes patients were unable to access semaglutide due to off-label …
-
Free webinar: Ensuring compliance-first logistics for reliable clinical trials
According to GlobalData, industry-sponsored trials have increased from 7,721 in 2016 to 13, 685 in 2025. This growth over the …
-
Pfizer and Novavax ink $530m vaccine delivery licensing deal
Pfizer has signed a deal worth up to $530m with US-based vaccine technology company Novavax. This agreement will see Pfizer hand …
-
BMS and Microsoft partner for AI-based lung cancer detection
Bristol Myers Squibb (BMS) has entered an agreement with Microsoft to advance AI-driven early lung cancer detection. The collaboration will deploy …
-
Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies
Novo Nordisk and Aspect Biosystems have commenced a new phase in their ongoing partnership focused on curative cellular medicines to …
-
Innovations in Dermatology Trials: Embracing Digital Tools and Decentralized Approaches
Skin disease has a growing profile in drug development. New immuno-dermatology agents, topical biologics and cell-based treatments are moving through …
-
When trillion‑member libraries meet physics: what diversity really means
Dr Karsten Eastman, CEO, Sethera Therapeutics, highlights the challenges around ‘true’ diversification in DNA libraries. In drug discovery, big numbers for …
-
Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up
As Pfizer sells its stake in ViiV Healthcare, Japan-based Shionogi & Co will increase its hold in the human immunodeficiency …
